Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11391-11402
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Table 4 Comparison of adverse events between the two groups
Item | Control group | TCM group | P value | ||
n = 38 | Percent (%) | n = 40 | Percent (%) | ||
Gastroenteritis | 24 | 63.1 | 12 | 30.0 | 0.006 |
Anemia | 5 | 13.1 | 2 | 5.0 | 0.970 |
Hepatic function damage | 16 | 42.1 | 9 | 22.5 | 0.030 |
Leukopenia | 3 | 7.8 | 0 | 0 | 0.060 |
Upper respiratory infection | 5 | 13.1 | 7 | 17.5 | 0.590 |
Phlebothrombosis | 2 | 5.3 | 0 | 0 | 0.140 |
Urinary infection | 1 | 2.6 | 0 | 0 | 0.300 |
Hypothyroidism | 3 | 7.9 | 1 | 2.5 | 0.280 |
Hypertension | 10 | 26.3 | 3 | 7.5 | 0.020 |
- Citation: Cao TT, Chen L, Zhen XF, Zhao GJ, Zhang HF, Hu Y. Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study. World J Clin Cases 2022; 10(31): 11391-11402
- URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11391.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11391